Clinical Trial

ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

Study acronym: VICTORIA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that the epigenetic agent valproic acid improve the activity of anti-EGFR agents, prevent and revert the emergence of EGFR resistance, in a rechallenge setting. Correlative mechanistic studies on tissue and blood samples, liquid biopsies, could identify potential biomarkers of efficacy and help understanding the evolutionary dynamics of tumors in response to therapy thus optimizing the treatment approach with a personalized anti- EGFR treatment strategy.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-11-28; most recent amendment 2025-12-16.
Status change: Not Yet Recruiting → Recruiting 2025-05-28
Trial Details
NCT Number NCT06714357
Lead Sponsor National Cancer Institute, Naples
Conditions Colorectal Cancer Metastatic
Enrollment 130 participants
Start Date 2025-03-12
Primary Completion 2026-12-20 (estimated)
Study Completion 2027-06-20 (estimated)
Updated on ClinicalTrials.gov 2025-12-17